Who are the leading innovators in DNA polymorphism testing for the pharmaceutical industry? | So Good News
Pharmaceutical the industry remains a hotbed of innovation, driven by the evolution of new treatment paradigms, the severity of unmet need, and the importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence (AI). According to GlobalData’s report on Artificial Intelligence in Pharmaceuticals: DNA Polymorphism Detection, more than 633,000 patents have been filed and granted in the pharmaceutical industry in the last three years alone.
However, not all innovations are the same and they do not follow a constant growth trend. Instead, their evolution takes an S-shaped curve, showing their typical life cycle from early emergence to accelerating adoption before finally stabilizing and maturing.
Determining where a particular innovation is on this journey, especially those in the emerging and accelerating stages, is critical to understanding their current level of adoption and their likely future trajectory and impact.
110 creates innovations pharmaceutical industry
According to GlobalData Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models based on more than 756,000 patents, there are 110 innovation areas shaping the future of the industry.
inside to appear Innovations in AI, DNA chips, automation of tissue culture, and mass spectrometry analysis are examples of disruptive technologies that are in the early stages of adoption and should be closely monitored. DNA binding site prediction, peptide structure optimization and genome analysis using AI acceleration Areas of innovation for AI in the pharmaceutical industry, where adoption is steadily increasing. between maturity Areas of innovation are in silico drug discovery, DNA polymorphism detection, and genome sequence analysis, which are now well established in the industry.
innovation S-curve for artificial intelligence inside pharmaceutical industry
Determination of DNA polymorphism is the main innovative field artificial intelligence
The study of human genetic variation has provided insight into common and rare diseases, accelerated the pace of drug development, and paved the way for the future of precision medicine. The study of genotypic analysis identifies complex relationships between genotype and phenotype, and also focuses on single nucleotide polymorphisms (SNPs), insertion or deletion polymorphisms (indels), and copy number variants (CNVs).
GlobalData’s analysis also reveals the companies at the forefront of each innovative area and assesses the potential reach and impact of their patenting activities in different applications and geographies. According to GlobalData, there are 80+ companies involved in the development and application of DNA polymorphism detection, including technology vendors, established pharmaceutical companies, and up-and-coming startups.
Key players in DNA polymorphism detection are a disruptive innovation in the pharmaceutical industry
“Application diversity” measures the number of different applications identified for each relevant patent and broadly divides companies into “niche” or “diversified” innovators.
“Geographic reach” refers to the number of different countries in which each relevant patent is registered and indicates the range of geographic application, ranging from “global” to “local”.
Thermo Fisher Scientific is one of the innovators in genotyping. It offers a comprehensive portfolio of genotyping solutions for SNP, indel and CNV analysis. It also offers solutions such as genotyping microarrays, real-time polymerase reaction (PCR) for genotyping, targeted genotyping by sequencing, digital PCR for genotyping, fragment analysis by capillary electrophoresis and in situ hybridization.
Axcella Health is the leading company in terms of application diversity, followed by Pronutria Biosciences and Curevac. In terms of geographic reach, Baxter International ranks high. TRON and the Center for Addiction and Mental Health are in second and third place, respectively.
For a deeper understanding of the key topics and technologies disrupting the pharmaceutical industry, access GlobalData’s latest Topical Research Report on Artificial Intelligence (AI) in Healthcare – Topic Research.